Despite a slight slowdown, there’s considerable cash already sloshing around the biotech IPO space. There’s (still!) plenty more stacked up in investor suitcases from California to the New York Island just waiting to back anything with a pulse. The momentum is here! This land grab is your land grab!
All of which should mean that biotech boards weighing exit options the past year or so have had choices that didn’t exist for most companies in the preceding four or...